PDS Biotechnology Stock

PDS Biotechnology EBITDA per Employee

The EBITDA per Employee of PDS Biotechnology (PDSB) as of Aug 10, 2026 is -2.10 M USD. In the previous year, EBITDA per Employee was -2.42 M USD — a change of -13.15% (higher).

EBITDA per Employee

-2.10 MUSD

YoY

-13.15%

Last updated:

EBITDA per Employee of PDS Biotechnology is 2026 -2.10 M USD. EBITDA per Employee of PDS Biotechnology was 2025 -2.42 M USD. It decreases by -13.15% higher compared to the previous year.
Access this data via the Eulerpool API

PDS Biotechnology Stock analysis

What does PDS Biotechnology do? PDS Biotechnology Corporation is a biopharmaceutical company founded in 2005. It is based in New Jersey, USA and employs around 35 employees. The company specializes in the development of drugs and therapies for the treatment of cancer and infectious diseases. PDS Biotechnology's business model is based on the use of a technology platform called Versamune®. This platform allows for the embedding of immunomodulatory agents in vaccines and cancer therapies. The goal is to activate and strengthen the body's immune defense against cancer and infections. PDS has four different divisions: cancer immunotherapies, infectious diseases, vetmedica, and research services. PDS's cancer immunotherapies focus on stimulating the immune system to help the body recognize and fight cancer cells. The Versamune® technology is used in combination with peptide-based vaccines. Versamune® is intended to help generate a strong and sustained immune response. The most advanced projects in cancer immunotherapy include PD1 vaccines and the PD1 vaccine combination program. PDS is also working on the development of Versamune®-based treatment options in the areas of infectious diseases and vetmedica. Advanced platform technologies have been developed based on the use of Versamune® and choice peptide fusion proteins. In the field of research services, PDS offers a range of services related to its technology platform. These include the manufacturing of Versamune® products, preclinical studies, as well as analysis and consulting. One of PDS's projects, currently being tested in clinical phase IIa, is a vaccine against human papillomavirus (HPV). HPV is a virus that plays a significant role in the development of various types of cancer, such as cervical cancer. The vaccine aims to strengthen the immune system against HPV and thereby reduce the risk of developing cancer. In addition to developing new drugs, PDS has also focused on improving existing treatment options. The company collaborates closely with research institutions and other companies to leverage new insights and technologies in order to develop better therapies. PDS Biotechnology is an emerging company with promising products and a strong commitment to developing groundbreaking therapies for the treatment of cancer and infectious diseases. Through the use of its Versamune® technology and expertise in immunotherapy, the company has the potential to change the future of medicine and improve the lives of millions of people. PDS Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PDS Biotechnology stock

EBITDA per Employee of PDS Biotechnology is -2.10 M USD in 2026.

EBITDA per Employee of PDS Biotechnology changed from -2.42 M USD to -2.10 M USD, representing a -13.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee PDS Biotechnology since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's PDS Biotechnology historically and in real time.

Access this data via the Eulerpool API

Workforce — PDS Biotechnology

All Key Metrics — PDS Biotechnology